Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Financials
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
199.65 USD   +3.40%
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's Disease to FDA
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 53 54337 67935 24229 239--
Enterprise Value (EV)1 51 73341 72337 82030 05925 96922 199
P/E ratio 9,44x9,87x23,1x14,2x12,3x13,2x
Yield ------
Capitalization / Revenue 3,72x2,80x3,21x2,97x3,11x3,11x
EV / Revenue 3,60x3,10x3,44x3,06x2,76x2,36x
EV / EBITDA 6,41x5,56x9,13x8,40x7,25x5,99x
Price to Book 3,87x3,70x3,26x2,30x1,99x1,75x
Nbr of stocks (in thousands) 180 442153 882146 893146 452--
Reference price (USD) 297245240200200200
Announcement Date 01/30/202002/03/202102/03/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 14 37813 44510 9829 8349 3969 391
EBITDA1 8 0707 5044 1443 5773 5843 706
Operating profit (EBIT)1 7 3906 8373 6562 9622 9742 953
Operating Margin 51,4%50,9%33,3%30,1%31,7%31,4%
Pre-Tax Profit (EBT)1 7 1265 0481 7452 3443 1072 834
Net income1 5 8894 0011 5561 9962 2772 057
Net margin 41,0%29,8%14,2%20,3%24,2%21,9%
EPS2 31,424,810,414,116,215,1
Dividend per Share2 ------
Announcement Date 01/30/202002/03/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 2 7792 7342 5322 4862 4382 401
EBITDA1 1 018781844843901884
Operating profit (EBIT)1 885646709784762692
Operating Margin 31,9%23,6%28,0%31,5%31,3%28,8%
Pre-Tax Profit (EBT)1 291405347837617578
Net income1 329368304734509467
Net margin 11,8%13,5%12,0%29,5%20,9%19,5%
EPS2 2,222,502,065,543,603,24
Dividend per Share ------
Announcement Date 10/20/202102/03/202205/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 -4 0442 578819--
Net Cash position1 1 810---3 2707 040
Leverage (Debt / EBITDA) -0,22x0,54x0,62x0,23x-0,91x-1,90x
Free Cash Flow1 6 5643 8053 3822 5042 8332 844
ROE (Net Profit / Equities) 47,7%45,2%26,6%19,1%17,2%15,9%
Shareholders' equity1 12 3428 8415 85810 47613 26412 952
ROA (Net Profit / Asset) 24,0%15,4%11,9%8,74%8,58%8,40%
Assets1 24 58325 92713 12422 85526 54524 483
Book Value Per Share2 76,666,273,586,9101114
Cash Flow per Share2 38,026,224,319,219,620,5
Capex1 515425258277280288
Capex / Sales 3,58%3,16%2,35%2,82%2,98%3,07%
Announcement Date 01/30/202002/03/202102/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
Key data
Capitalization (USD) 29 239 144 395
Net sales (USD) 10 981 700 000
Number of employees 9 610
Sales / Employee (USD) 1 142 737
Free-Float 85,4%
Free-Float capitalization (USD) 24 976 328 827
Avg. Exchange 20 sessions (USD) 266 490 105
Average Daily Capital Traded 0,91%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA